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1. Introduction 
Hormonal regulation of the growth of breast cancer cells has been largely seen to result from 
interactions of estrogen and progestins with nuclear receptors for these steroids that may 
reside, unliganded, in cytoplasm or be transcriptionally active as steroid-protein nuclear 
receptor complexes. Receptors for nonpeptide hormones exist in the plasma membrane, 
however, and when activated may stimulate breast cancer cell proliferation. For example, 
the functional classical estrogen receptor-α (ERα) is found in the cell membrane. Recently, 
the identification has been made of a novel receptor for thyroid hormone and for 
dihydrotestosterone (DHT) on the plasma membrane of cells; this receptor is the αvβ3 
integrin, which promotes proliferation of human breast cancer cells by these two hormones. 
Integrins are heterodimeric structural proteins of the plasma membrane whose primary 
functions are to interact with extracellular matrix proteins and growth factors. One integrin, 
αvβ3, bears discrete receptors for thyroid hormone (L-thyroxine, T4; 3, 5, 3’-triiodo-L-
thyronine, T3) and for DHT. A receptor for the polyalcohol, resveratrol, also exists on this 
integrin in breast cancer cells, mediating the anti-proliferative, pro-apoptotic action of this 
compound. Resveratrol has certain structural features that are estrogen-like. Disparate 
actions of T4, T3, DHT and resveratrol that are initiated at the integrin depend downstream 
upon stimulation of the activity of mitogen-activated protein kinase (MAPK), suggesting the 
existence of distinct, function-specific pools of MAPK within the cell. Tetraiodothyroacetic 
acid (tetrac) is a model specific inhibitor of hormone actions on the thyroid hormone 
integrin receptor. Tetrac and a nanoparticulate formulation of tetrac block stimulation by 
thyroid hormone analogues of cancer cell proliferation and of angiogenesis. Interestingly, 
tetrac also acts in the absence of T4 and T3 to block the tumor-relevant angiogenic responses 
to vascular growth factors, e.g., vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF) and other growth factors. Tetrac and nanoparticulate tetrac also 
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disable expressions of families of genes important to cancer cell survival pathways. This 
chapter reviews the functions of the several nonpeptide hormone receptors on integrin 
αvβ3.   
The possibility that the hormone-directed biology of the breast cancer cell might be in part 
regulated from the cell surface was first suggested by the identification of estrogen receptor 
protein in the plasma membrane (Levin, 1999). Discrete receptors on the plasma membrane 
αvβ3 integrin of breast cancer cells have also recently been described for thyroid hormone 
(Bergh et al., 2005; Cheng et al., 2010; Davis, P. et al., 2011), for dihydrotestosterone (DHT) 
(Lin, H. et al., 2009b) and for resveratrol (Lin, H. et al., 2006). The several functions of these 
membrane receptors include modulation of cancer cell proliferation and, in the case of 
thyroid hormone, of tumor-relevant angiogenesis (Cheng et al., 2010; Mousa et al., 2009). 
Expression of integrin αvβ3 is concentrated in tumor cells and rapidly-dividing endothelial 
and vascular smooth muscle cells, so that receptors for these hormones—and resveratrol is a 
polyalcohol with estrogen-like structural features—may be considered targets for 
manipulation of breast cancer. In the present review we will describe the features of these 
receptors in the breast cancer cell, and will also propose clinical therapeutic applications that 
are based on inhibition of these small molecule plasma membrane receptors.  
2. Thyroid hormone stimulates human breast cancer cell proliferation via 
plasma membraneiIntegrin αvβ3 
In the absence of estrogen, thyroid hormone (L-thyroxine [T4]) was shown in 2004 to 
enhance proliferation of human estrogen receptor-α (ERα)-positive breast cancer cells (Tang 
et al., 2004). The thyroid hormone effect required extracellular-regulated kinases 1 and 2 
(ERK1/2)-dependent phosphorylation of Ser-118 of ERα, precisely mimicking the action of 
estradiol (Kato et al., 1995) on breast cancer cell proliferation. The nuclear estrogen receptor 
inhibitor ICI 182,780 (Fulvestrant®)  blocked this action of thyroid hormone (Lin H. , 
unpublished), as did tetraiodothyroacetic acid (tetrac), an analogue of T4 in which the 
alanine side chain of T4 is converted to acetic acid (Tang et al., 2004). Tetrac is an inhibitor of 
actions of T4 and T3 that are initiated at the thyroid hormone receptor site on integrin αvβ3 
(Bergh et al., 2005; Yalcin et al., 2010a; Yalcin et al., 2010b; Davis, F. et al., 2006). Studied in 
vitro, T4 and T3 are anti-apoptotic in breast cancer cells (Tang et al., 2004) and other tumor 
cells (Lin et al., 2008a), at least in part via a mechanism that blocks effectiveness of the 
oncogene suppressor protein and pro-apoptotic factor, p53 (Lin et al., 2011).  
Acting via the plasma membrane integrin receptor, agonist thyroid hormone analogues T4 
and T3 are also pro-angiogenic (Mousa et al., 2009; Davis, P. et al., 2009; Luidens et al., 2010). 
In the absence of tumor cells and in the setting of tissue ischemia, stimulation of 
neovascularization by T4 and T3 may be desirable (Tomanek et al., 1998; Chen et al., 2010). In 
the setting of cancer, however, these agents appear to enhance tumor-related angiogenesis. 
The mechanism of angiogenesis is complex and involves the release by endothelial cells of 
vascular growth factors (Tomanek et al., 1998) and the resulting autocrine effects of such 
factors. T4 and T3 may also enhance the actions of vascular growth factors (Davis, F. et al., 
2004).  
The effectiveness of tetrac as an inhibitor of actions of T4 and T3 on the plasma membrane of 
cancer cells caused us to study tetrac as an anti-cancer and anti-angiogenic agent. We found 
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that unmodified tetrac as well as tetrac re-formulated as a nanoparticulate, in which it is 
covalently bound to poly-lactic-co-glycolic acid (PLGA), have anti-proliferative effects in 
tumor cells. These actions reflect the ability of tetrac and nanoparticulate tetrac to 1) 
antagonize the pro-proliferative, anti-apoptotic actions of T4 and T3; 2) to disable, in the 
absence or presence of T4 and T3, the expression of a number of survival pathway genes 
(Glinsky et al., 2004); and 3) to suppress the death-from-cancer gene signature of a number of 
cancer cell lines (Glinsky et al., 2005). This 11-gene signature is a predictor of aggressiveness 
of cancer cells as demonstrated by shortened "time-to-tumor recurrence", the presence of 
distant metastasis, and death after tumor therapy. The PLGA formulation of tetrac acts 
exclusively at the integrin receptor for thyroid hormone; in contrast, unmodified tetrac acts 
at the integrin, but also gains access to the interior of the cell and may mimic actions of T4 
(Moreno et al., 2008). 
Actions of nanoparticulate tetrac on gene expression in human breast cancer cells are 
coherent (Glinskii et al., 2009). While the expression of a number of cyclin genes is 
suppressed and anti-apoptotic gene expression is decreased, pro-apoptotic gene expression 
is enhanced. Fairly remarkably, the expression of thrombospondin 1 (TBSP1) is increased. The 
TBSP1 protein is anti-angiogenic and the protein rarely accumulates in cancer cells. 
Nanoparticulate tetrac can also suppress expression of the epidermal growth factor receptor 
(EGFR) whose gene product supports cancer growth and angiogenesis and whose receptor 
is an oncologic target (Glinskii et al., 2009). In the same study, however, while unmodified 
tetrac blocked expression of cyclin genes and certain genes relevant to apoptosis, this 
unmodified form of tetrac did not affect EGFR expression. Thus, the fit of the 
nanoparticulate formulation into its receptor on integrin αvβ3 appears to be distinct from 
that of tetrac, itself. Nanoparticulate tetrac is also 10- to 100-fold more potent than 
unmodified tetrac, depending on the particular cell line studied (Glinskii et al., 2009; Yalcin 
et al., 2010a; Yalcin et al., 2010b).  
These observations on the two formulations of tetrac are consistent with the complexity of 
the receptor for thyroid hormone on the integrin (Cody et al., 2007) and with the ability of 
the integrin to generate a spectrum of intracellular actions via several signal-transducing 
kinase pathways, including MAPK (extracellular-regulated kinases 1/2, or ERK1/2) and 
phosphatidyl-inositol 3-kinase (PI3K). Studied in human glioma cells by mathematical 
modeling of the kinetics of binding, the receptor site appears to contain two thyroid 
hormone-binding domains, one that recognizes only T3 and a second that transduces both 
the T4 and T3 signals (Lin et al., 2009c). Recent computer graphics analysis of the interactions 
of T3 and T4 with the integrin (V. Cody, unpublished observations) is consistent with the 
existence of two hormone-binding domains in the receptor.  While tetrac and nanotetrac 
interact with both domains, they do so differently, as the resulting gene expression profiles 
obtained in breast cancer cells indicate (Glinskii et al., 2009).  
It is important to note that the integrin-mediated anti-angiogenic activity of tetrac and 
nanotetrac transcend the inhibition of the pro-angiogenic thyroid hormone agonists, T4 and 
T3. That is, in the absence of agonist thyroid hormone, tetrac can block the actions of 
vascular endothelial growth factor (VEGF) (Mousa et al. , 2008), bFGF (FGF2) (Mousa et al. , 
2008), platelet-derived growth factor (PDGF) (SA Mousa: unpublished observations) and, as 
mentioned above, EGF. Because tumor cells can secrete multiple vascular growth factors to 
support their needs, it is desirable to identify potential therapeutic agents that antagonize 
the actions of more than one such growth factor.  
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It is clear from the foregoing that the actions of tetrac formulations at the cell surface 
integrin and of T4 and T3 at αvβ3 generate complex downstream events. However, it is also 
apparent that the hormone receptor on the integrin can also engage in crosstalk with growth 
factors on the plasma membrane. Interference by tetrac formulations with the actions of 
VEGF, bFGF and other growth factors imply this, since such growth factors include Arg-
Gly-Asp (RGD) sequences that are validated by the RGD recognition site on the integrin 
before each growth factor can activate its growth factor-specific receptor clustered with the 
integrin (Davis, P. et al., 2011). The αvβ3-vascular growth factor receptor interaction, e.g., 
with VEGF (Sarmishtha et al., 2005) and bFGF (Sahni and Francis, 2004), have been 
described in other studies that did not include thyroid hormone. The integrin receptor for 
agonist thyroid hormone analogues and for tetrac, however, influences other local cell 
membrane events. For example, activity of the Na+/H+ exchanger (NHE1) is regulated by 
thyroid hormone analogues and this action is blocked by tetrac (Incerpi et al., 2003). The 
insertion of Na, K-ATPase protein into the plasma membrane and activity of the ATPase 
(sodium pump) are also affected nongenomically by a MAPK- and PI3K-dependent 
mechanism (Lei et al., 2007).  
Such observations caused us to examine in doxorubicin-resistant human breast cancer cells 
(MCF-7) whether the state of resistance, in part determined by the expression and activity of 
the P-glycoprotein (MDR) pump (Dönmez et al., 2010), may be affected by tetrac. Treatment 
of such breast cancer cells with tetrac reversed chemoresistance of the cells and resulted in 
increased intracellular residence time of radiolabeled doxorubicin (Rebbaa et al., 2008). Such 
in vitro studies suggest that the combination of tetrac and doxorubicin should be tested in 
xenografts of doxorubicin-resistant MCF-7 cells. The mechanism of this particular action of 
tetrac has not been established. While it is possible that the function of the P-glycoprotein is 
affected by crosstalk with the tetrac-occupied hormone receptor on the integrin, we have 
also suggested that the action of tetrac on the NHE may be involved (Incerpi et al., 2003). 
That is, inhibition of the NHE and a resultant intracellular decrease in pH may affect P-
glycoprotein function because of the pH optimum of the MDR pump. 
We would also point out that tetrac radiosensitizes tumor cells (Hercbergs et al., 2009) by 
interfering with repair of DNA double-strand breaks (Hercbergs et al., 2011). However, this 
has been studied to-date only in murine and human glioma cells and whether the agent 
affects DNA repair in breast cancer cells is not yet known. 
A final consideration with regard to thyroid hormone is the recently described effect of the 
hormone on the abundance of integrin αvβ3 on the tumor cell plasma membrane. Agonist 
thyroid hormone analogues have a modest effect on the expression of the αvβ3 gene (Yonkers 
et al., 2009) and may also increase the internalization of the αv, but not the β3 component (Lin 
et al., 2009).  The disparate distribution of the αv and β3 monomers within the cell is also 
conditioned by thyroid hormone, including import of αv into the cell nucleus (Lin et al., 2007).  
3. Actions of resveratrol and the integrin receptor on the biology of breast 
cancer cells 
Resveratrol is an extensively-studied, naturally-occurring alcohol with desirable properties in 
several biologic models. These activities include extension of lifespan in C. elegans (Zarse et al., 
2010) and remarkable anti-cancer properties (Pezzuto et al., 2011; Hsieh et al., 2011; Lin, C et al., 
2011). Substantial attention has been devoted to the metabolism of this agent because of its 
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rapid disappearance from the circulation post-administration to intact animals and its cellular 
uptake and chemical modification (Delmas et al., 2011). The half-life of the parent compound is 
sufficiently short to promote speculation about the nature of the active biologic material.  
We recently described a cell surface receptor for resveratrol on breast cancer cells which, like 
the thyroid hormone receptor on tumor cells (Bergh et al., 2005), is on integrin αvβ3 (Lin et 
al., 2006). The existence of such a receptor and its ability to transduce the plasma membrane 
resveratrol signal into MAPK activity and downstream into pro-apoptotic action suggested 
that the parent compound has substantial bioactivity. Integrins have been widely-viewed to 
bear receptors or binding sites only for large molecules—extracellular matrix proteins and 
growth factors (Plow et al., 2000)—and thus it was surprising to find apparent biologically 
relevant binding sites for two small molecules on this integrin. It was also remarkable that 
the receptors for thyroid hormone and for resveratrol did not appear to interact functionally 
with one another. That is, both agents activated intracellular pools of MAPK (ERK1/2), but 
resveratrol was pro-apoptotic (Lin H et al., 2008a; Lin C et al., 2011) whereas thyroid 
hormones (T4, T3) were anti-apoptotic (Lin H et al., 2008b), as noted above. Such 
observations suggested that the results of any efficacy testing of resveratrol as a 
chemotherapeutic agent in the presence of physiologic concentrations of thyroid hormone in 
vitro or in the intact animal with a normal pituitary-thyroid axis may be difficult to interpret 
(see below). An Arg-Gly-Asp (RGD) peptide prevents both the pro-apoptotic activity of 
resveratrol and the anti-apoptotic activity of thyroid hormone, indicating that the receptor is 
near the RGD recognition site on the integrin that was mentioned above (see section on 
Thyroid Hormone Action). The interactions of tetrac with either T4 or resveratrol, however, 
indicate that the two integrin binding sites are distinct, in that while tetrac inhibits the 
proliferative action of T4 in cancer cells, tetrac does not inhibit the pro-apoptotic actions of 
resveratrol (Lin C et al., 2011). 
Our own studies of the mechanism by which resveratrol may act to induce apoptosis in 
tumor cells have revealed several unexpected findings. First, resveratrol is able to induce 
p53-related apoptosis in cancer cells expressing certain mutations in p53. What is required in 
p53 for expression of resveratrol’s apoptotic activity is that the Ser-15 be intact, as it is a 
target of phosphorylation by resveratrol-activated MAPK (Lin H et al., 2002). Second, one of 
the actions of resveratrol in tumor cells is to induce a nuclear pool of cyclooxygenase-2 
(COX-2) (Lin C et al., 2011; Lin H et al., 2009a). Chronic accumulation of COX-2 in cytoplasm 
is a marker of tumor cell aggressiveness (Schmitz et al., 2006; Perdiki et al., 2007) and long-
term pharmacologic inhibition of the enzymatic activity of COX-2—the product of which is 
prostaglandins—appears to improve clinical outcomes or prevent emergence of certain 
cancers, such as that of the colon (Galalmb et al., 2010).  
Inducible COX-2 in the nucleus, however, is a wholly different biologic product. It is pro-
apoptotic, can interact with Ser-15-phosphorylated p53 and can even bind to DNA (Lin H et 
al., 2008b). The latter observation raises the possibility that COX-2 can be a co-activator and, 
indeed, resveratrol-induced nuclear COX-2 co-localizes with p300, a coactivator for p53 
(Song et al., 2010), as well as for proteins in the superfamily of nuclear hormone receptors 
(Kalkhoven, 2004). Activation of MAPK is required for formation of the complex of p53, 
p300 and COX-2, since that complex is not obtained in resveratrol-treated cells in the 
presence of the MEK-MAPK inhibitor, PD 98059 (Tang et al., 2006). In contrast, inhibition of 
the enzymatic activity of COX-2 with indomethacin does not affect the pro-apoptotic activity 
of COX-2 (Tang et al., 2006).   
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Third, a thyroid hormone analogue such as T4 prevents or disrupts the formation of the 
nuclear p53-COX-2 complex in cells treated with resveratrol (Lin et al., 2008a, b). It is 
thought that this hormonal effect explains the blunting of the pro-apoptotic action of 
resveratrol in the presence of thyroid hormone. Competition between thyroid hormone and 
resveratrol for binding to the αvβ3 integrin is thought to be responsible for this inhibition. 
Not unexpectedly, in a tumor cell system that includes resveratrol and a physiologic 
concentration of T4, the addition of tetrac protects the pro-apoptotic action of resveratrol 
from the anti-apoptotic effect of thyroid hormone (Lin et al., 2008b). All of these actions 
compete at the αvβ3 integrin receptor. In the absence of T4, the induction of apoptosis by 
resveratrol is not affected by the addition of tetrac (Lin et al., 2008b).   
The antecedent review suggests that further testing of resveratrol as a cancer 
chemotherapeutic agent might be pursued in two ways. First, the combination of nanotetrac 
and resveratrol may be evaluated against breast tumor cells in vitro or in vivo in the nude 
mouse xenograft model. Second, the potential manufacture of a nanoparticulate formulation 
of resveratrol in which the polyalcohol is covalently bound to the nanoparticle may be 
desirable, so as to permit biologic activity but restrict that effect of resveratrol to the integrin 
receptor. This formulation would prevent cellular uptake and subsequent 
metabolism/degradation of the nanoparticulate compound.  
There is another implication with regard to the dependence of the pro-apoptotic action of 
resveratrol on an inducible pool of nuclear COX-2. New pharmacologic inhibitors of the 
enzymatic function of cyclooxygenase-2 should be examined for their ability to block the 
action of resveratrol, and perhaps of other polyalcohols as model inducers of nuclear COX-2. 
For example, NS398 is an experimental inhibitor of COX-2 that has been shown to prevent 
induction of COX-2 by resveratrol (Tang et al., 2006). 
4. Dihydrotestosterone (DHT) acts via integrin αvβ3 to induce proliferation of 
human breast cancer cells 
Although androgens may have an inhibitory effect on the proliferation of breast cancer cells, 
the actions of these steroids on such cells are variable. When we examined the action of 
dihydrotestosterone (DHT) on ERα-positive MCF-7 and ERα-negative MDA-MB-231 human 
breast cancer cells, we found that the androgen promoted proliferation in both cell lines (Lin 
et al., 2009b). Integrin αvβ3 antibody inhibited the action of DHT in MDA-MB-231 cells, but 
was ineffective in MCF-7 cells (Lin et al., 2009b). On the other hand, ICI 182,780 treatment 
and siRNA knockdown of ERα blocked the proliferative effect of DHT in MCF-7 cells, but 
not in the MDA-MB-231 cells. Thus, the mechanisms of DHT action differ in the two cell 
lines, and only in the ER-negative cells was there evidence for the existence of a DHT 
receptor on integrin αvβ3.   In neither breast cancer cell line could participation of a classical 
androgen receptor be implicated in the action of DHT. Tetrac did not affect the action of 
DHT (HY Lin: unpublished observations), indicating that these two small molecule 
receptors on the integrin function independently of one another. 
It is not yet clear what the clinical significance may be of the DHT receptor on the breast 
cancer cell surface. We speculate, however, that in the patient with a recurrent ERα-positive 
tumor and taking tamoxifen or an aromatase inhibitor, residual circulating androgen may be 
promoting cancer cell proliferation. Useful information relevant to this possibility will come 
from determination of the androgen analogue-specificity of the receptor for DHT, and of a 
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possible contribution of DHT to breast cancer cell growth. In the case of the ER-negative 
human breast cancer cell, we have already demonstrated its susceptibility to DHT-
stimulation (Lin et al., 2009b). 
It will also be important to analyze solid tumors beyond breast cancer for the presence of 
DHT-induced growth stimulation, including cancer cell growth as well as angiogenesis. In a 
recent report, Sieveking et al. (2010) have reported that androgen treatment of male 
endothelial cells in vitro enhanced angiogenesis; in contrast, gene knockdown of the 
androgen receptor (AR) in these cells caused unresponsiveness of these cells to androgen 
treatment. Female endothelial cells lacking AR did not respond to androgen treatment, but 
overexpression of the androgen receptor in female endothelial cells caused angiogenesis to 
occur. 
5. Discussion and conclusions 
Modulation of the proliferation of breast cancer cells is largely viewed as a function of the 
presence or absence of estrogen in ER-positive tumor cells and the presence of polypeptide 
growth factors that are autocrine or systemic. The emphasis on ER-mediated actions has 
grown from a broad understanding, emerging from a number of laboratories, of the 
molecular functions of ER in the cell nucleus and genomic actions of estrogens. Management 
of breast cancer—beyond surgery, tumor irradiation and chemotherapeutic agents—
specifically emphasizes suppression of the action of endogenous estrogen with tamoxifen or 
inhibition of estrogen synthesis with aromatase inhibition. That estrogen may support breast 
tumor growth nongenomically is now under consideration (Silva & Shupnik, 2007), perhaps 
involving nuclear ERα insinuated into the plasma membrane or ER-like proteins in the 
membrane (Levin, 2011).  
The concept that thyroid hormone may be a growth factor for breast cancer has been 
advanced by various investigators (Goodman et al., 1980; Borek et al., 1983; Cristofanilli et al., 
2005).  That thyroid hormone could nongenomically support ER-positive human breast 
cancer cell proliferation and to be estrogen-like was shown when T4 caused MAPK-
dependent specific serine phosphorylation of nuclear ER, mimicking estradiol upon which 
depended stimulation of proliferation by the iodothyronine. This work led to the 
subsequent identification of a thyroid hormone receptor on plasma membrane integrin αvβ3 
at which a variety of effects of thyroid hormone are initiated that are nongenomic in 
mechanism (Tang et al., 2004). The integrin (and, therefore, the receptor) is expressed 
primarily on cancer cells of various types and on rapidly-dividing blood vessel cells 
(Dijkgraaf et al., 2009; Wei  et al.,2009; Dimastromatteo  et al., 2010).  
An interesting inhibitor of this receptor target exists. This is tetraiodothyroacetic acid 
(tetrac), a deaminated analogue of T4 that blocks binding of T4 and T3 to the integrin, but 
also has novel anti-cancer activities at the αvβ3 hormone-binding site in the absence of T4 
and T3. These actions, initiated at the cell surface, are on expression of specific genes and the 
actions are inimical to tumor cell survival and on angiogenesis (Glinskii, A. et al., 2009), 
including that initiated by several vascular growth factors. The hormone receptor on the 
integrin also disables or garbles crosstalk between the integrin and growth factor receptors 
that are clustered with αvβ3 (Davis, F. et al., 2004; Mousa S. et al., 2008).   
Tetrac has been re-formulated as a nanoparticle in which the outer ring hydroxyl group is 
stably covalently bonded through a linker to the nanoparticle. This formulation does not 
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enter the cell and its actions are limited to the tetrac/thyroid hormone receptor on integrin 
αvβ3 (Bergh J. et al., 2005). The agent has been shown to suppress growth of a variety of 
human cancer cell xenografts and to be anti-angiogenic at the tumor site (Davis F. et al., 
2004; Davis F. et al., 2006; Glinskii A. et al., 2009; Davis P. et al., 2011). This hormone target on 
the integrin is fairly remarkable, in that as a single target, it has a relatively large number of 
downstream actions on cancer cells that emphasize vulnerability of such cells. 
Recognition and characterization of the thyroid hormone receptor on integrin αvβ3 were 
premonitory to the identification of other small molecule binding sites—now understood to 
be receptors in that, when occupied, they cause predictable downstream cellular events. 
These receptors appear to be quite independent of one another and of the thyroid hormone 
binding domain. Identification of the resveratrol receptor on the integrin of breast cancer 
cells and other solid tumor cells may provide useful insights into the actions of this stilbene. 
The rapid cellular uptake and metabolism of resveratrol (Kroon  et al., 2010)—leading to 
pharmacokinetic and pharmacodynamic speculation about the relative bioactivity of 
resveratrol analogues—is less puzzling if, in fact, the parent compound (resveratrol) can act 
on the outside of the cell. That is, resveratrol binds to the integrin and rapidly initiates a 
MAPK-requiring, p53-dependent apoptotic process, regardless of uptake of the compound 
and chemical processing. What was somewhat surprising was the observation that 
resveratrol-induced apoptosis was blocked by thyroid hormone, but by a mechanism that 
begins at a different domain on the integrin and utilizes MAPK, but is effected by 
interruption of a resveratrol-induced phosphorylation sequence in the cancer cell nucleus 
that involves p53 and other nucleoproteins. The outcomes of a recent pharmaceutical 
industry-sponsored clinical trial of resveratrol as an anti-cancer agent were disappointing 
(McBride, 2010). Where there may be multiple explanations for these results, we can 
speculate that in the setting of normal thyroid function that the anti-cancer activity of 
resveratrol may be wholly suppressed by the hormone. 
A third small molecule receptor on the integrin of breast cancer cells was recently described 
and this is a site that responds to the androgen, dihydrotestosterone (DHT) (Lin, H. et al., 
2009b). It was not wholly unexpected that an authentic steroid was found to act at the 
integrin, since resveratrol, while not a steroid, has certain structural features and functional 
activities that are estrogen-like. Acting via integrin αvβ3, DHT is a trophic agent for breast 
cancer cells. Of some interest is that the mechanisms by which DHT acts in vitro differ in 
ERα-negative and ERα-positive cells. The cell surface integrin receptor for DHT is required 
for the proliferative effect of the androgen in ERα-negative cells, but is irrelevant in ER-
positive cells, where the estrogen receptor protein, itself, is needed for DHT action. In 
neither type of cell is the authentic nuclear androgen receptor a part of the mechanism by 
which DHT recognizes the existence of a receptor on integrin αvβ3 in ERα-negative breast 
cancer cells. As we have pointed out above, recognition of the existence of the androgen 
receptor on αvβ3 in ERα-negative breast cancer may help to explain recurrences of tumor in 
postmenopausal women in whom some effect of circulating androgen, now apparent in the 
absence of estrogen, may be seen. 
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